1. The DOPPS Practice Monitor for US Dialysis Care: Trends Through December 2011 
Douglas S. Fuller, MS, Ronald L. Pisoni, PhD, MS, Brian A. Bieber, MPH, MS, Brenda W. Gillespie, PhD, Bruce M. Robinson, MD, MS 
American Journal of Kidney Diseases 
Volume 61, Issue 2, Pages (February 2013)
DOI: /j.ajkd
Copyright © 2013 National Kidney Foundation, Inc. Terms and Conditions

2. Figure 1
Change in ESA (erythropoiesis-stimulating agent) and IV (intravenous) iron treatment practices from October 2010 to October 2011, by September hemoglobin level. ESA and IV iron use represent prescription during a 1-month period. Weekly IV epoetin doses are estimated using 1-month values among treated patients. Monthly IV iron doses are estimated using 3-month averages among treated patients.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2013 National Kidney Foundation, Inc. Terms and Conditions

3. Figure 2
Change in selected facility treatment targets from 2010 to Abbreviation: PTH, parathyroid hormone. Based on medical directors surveyed at 59 DOPPS US study sites (the DOPPS 4 Medical Director Survey, conducted September to November 2011).
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2013 National Kidney Foundation, Inc. Terms and Conditions

4. Figure 3
Facility hemoglobin (Hb) threshold to start erythropoiesis-stimulating agent therapy in non–dialysis-dependent CKD and new dialysis patients. Based on the DOPPS 4 Medical Director Survey, conducted September to November 2011.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2013 National Kidney Foundation, Inc. Terms and Conditions

5. Figure 4
Facility hemoglobin (Hb) threshold for administering blood transfusions, 2010 and Abbreviation: CAD, coronary artery disease. Based on the DOPPS 4 Medical Director Survey, conducted September to November 2011.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2013 National Kidney Foundation, Inc. Terms and Conditions